Thursday, 30 July 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 30 July 2026
News

CSL's next-gen tech ready for trials

Posted 30 July 2026 AM

CSL has announced Phase 3 trials in its efforts to increase the yield of its plasma facilities, with an eye on regulatory approvals.

The next generation process to produce immunoglobulin, Horizon 2, will enter clinical trials to confirm efficacy and safety starting mid-2027. The patented technology enables significantly greater production of immunoglobulin from the same base amount of plasma. 

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (19)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (3)

Devices (1)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.